Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

Overview of attention for article published in Frontiers in oncology, July 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 2,454 followers.

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201) #lymphoma #lymsm https://t.co/aGX50S9Fyu

25 Jul 2022

Reply Repost Favourite

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201) #lymphoma #lymsm https://t.co/1bHNP2tsX7

25 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.